Post-Market Clinical Follow-up (PMCF) Study of Safety and Performance of 300-01 RefillHA Lips

September 15, 2026 updated by: Glyance

A Post-Market Observational Study of the Safety and Efficacy of RefillHA Lips for Remodelling and Correction of Mild Defects of the Lips.

A Post-Market Observational Study of the Safety and Efficacy of RefillHA Lips for Remodelling and Correction of Mild Defects of the Lips

Study Overview

Status

Recruiting

Detailed Description

This post-market, prospective, non-interventional, open label study is designed to demonstrate the performance and safety of RefillHA Lips in routine clinical practice for remodelling and correction of mild defects of the lips.

Subjects over 18 years old, willing to undergo non-surgical aesthetic procedures with RefillHA Lips will be offered to participate in the study. The investigators will enroll in any subject who receives at least one injection with RefillHA Lips and have provided informed consent. They will follow their routine practice regarding injection technique, volume, and subject follow-up. Treatments will be performed for a single indication or for multiple indications where correction is requested, subject to the advice of the practitioner and in accordance with the product intended use and conditions. Any indication can be retreated at any time throughout the duration of the study, as per routine practice. The area to be treated and injection characteristics - volume, depth, and technique - are all left to the discretion of the practitioner.

The study protocol includes an initial visit (baseline) and follow-up visits at months 1, 3, 6, 9, and 12 from baseline, in accordance with the non-interventional study design. Additional visits are allowed at any time throughout the follow-up period at the patient's request or when deemed necessary. At each visit, in addition to the safety assessment, performance will be evaluated through an area-specific assessment of the lips.

Study Type

Observational

Enrollment (Estimated)

87

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Israel
      • Lod, Israel, Israel, 7152026
        • Recruiting
        • Glyance Ltd
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Subjects over the age of 18 who are seeking remodelling and/or correction of mild defects of the lips.

Description

Inclusion Criteria:

  • Men or women of any race, 18 years of age or older.
  • Able to read, understand and sign informed consent.

Exclusion Criteria:

  • Subjects with known contraindications to the treatment with RefillHA Lips, as per the device IFU.
  • Patients with multiple and/or severe allergies or history of anaphylaxis.
  • Pregnant or lactating women (contraindications as per IFU).
  • Having received prior dermal filler injections in the six months preceding the study.
  • Previously treated with semi-permanent or permanent filler in the intended injection area.
  • Presenting with a cutaneous disorder, inflammation or infection near to the treatment area.
  • Known hypersensitivity to lidocaine and/or lidocaine HCl or hyaluronic acid.
  • Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder.
  • Undergoing or planning to undergo peeling treatment or laser-/ultrasound-based treatment within 3 weeks before or after injection.
  • Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed.
  • Subject who has a condition or is in a situation that, in the investigator's opinion, may put the subject at significant risk, or may significantly interfere with the subject's participation in the study or with protocol evaluation parameters.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Subjects over 18 years old, willing to undergo non-surgical aesthetic procedures with RefillHA Lips

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary endpoint
Time Frame: Up to 56 weeks after treatment

The proportion of subjects with Global Aesthetic Improvement Scale (GAIS) scores 1-3 (responders) in the lips at months 6, 9 and 12 after initial injection, as assessed by the investigator (iGAIS). [Scores 1-3 correspond to 'Very much improved', 'Much improved', and 'Improved' (see Section 12.1).]

Up to 56 weeks after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 18, 2024

Primary Completion (Estimated)

February 25, 2027

Study Completion (Estimated)

February 25, 2027

Study Registration Dates

First Submitted

September 15, 2026

First Submitted That Met QC Criteria

September 15, 2026

First Posted (Actual)

September 21, 2026

Study Record Updates

Last Update Posted (Actual)

September 21, 2026

Last Update Submitted That Met QC Criteria

September 15, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • PMCF-300-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe